Mary Wilson
Well-known member
Published online: 09 April 2021
https://doi.org/10.1007/s00134-021-06392-4
Rutger Koning1, Paul Bastard2,3,4, Jean?Laurent Casanova2,3,4,5, Matthijs C. Brouwer1
and Diederik van de Beek1* on behalf of the Amsterdam U.M.C. COVID?19 Biobank Investigators
Dear Editor,
Neutralizing autoantibodies (auto-Abs) against type I interferons (IFN-I) have been identi ed as risk factor for life-threatening coronavirus disease 2019 (COVID- 19) and were described in 101 of 987 (10%) patients with life-threatening pneumonia of whom 37 (37%) died [1]. In contrast, these antibodies were not found in patients with asymptomatic or mild disease and 0.33% of healthy individuals.
Auto-Abs against cytokines can cause severe or recur- rent infections by neutralizing their target cytokine [2]. Auto-Abs to IFN-I without neutralizing ability in vitro have been identi ed in COVID-19 patients, but their clinical signi cance is unclear. Here we describe clini- cal characteristics of COVID-19 patients with auto-Abs neutralizing IFN-I, a subset of patients described by Bas- tard et al. [1]. In addition, we investigate the role of auto- Abs against IFN-I that were not neutralizing in vitro in COVID-19 and non-COVID-19 patients. ...
https://link.springer.com/content/pdf/10.1007/s00134-021-06392-4.pdf
https://doi.org/10.1007/s00134-021-06392-4
Rutger Koning1, Paul Bastard2,3,4, Jean?Laurent Casanova2,3,4,5, Matthijs C. Brouwer1
and Diederik van de Beek1* on behalf of the Amsterdam U.M.C. COVID?19 Biobank Investigators
Dear Editor,
Neutralizing autoantibodies (auto-Abs) against type I interferons (IFN-I) have been identi ed as risk factor for life-threatening coronavirus disease 2019 (COVID- 19) and were described in 101 of 987 (10%) patients with life-threatening pneumonia of whom 37 (37%) died [1]. In contrast, these antibodies were not found in patients with asymptomatic or mild disease and 0.33% of healthy individuals.
Auto-Abs against cytokines can cause severe or recur- rent infections by neutralizing their target cytokine [2]. Auto-Abs to IFN-I without neutralizing ability in vitro have been identi ed in COVID-19 patients, but their clinical signi cance is unclear. Here we describe clini- cal characteristics of COVID-19 patients with auto-Abs neutralizing IFN-I, a subset of patients described by Bas- tard et al. [1]. In addition, we investigate the role of auto- Abs against IFN-I that were not neutralizing in vitro in COVID-19 and non-COVID-19 patients. ...
https://link.springer.com/content/pdf/10.1007/s00134-021-06392-4.pdf